1
|
Yang DD, Lee LK, Tsui JMG, Leeman JE, Lee KN, McClure HM, Sudhyadhom A, Guthier CV, Mouw KW, Martin NE, Orio PF, Nguyen PL, DAmico AV, King MT. Association between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy. Int J Radiat Oncol Biol Phys 2023; 117:e452-e453. [PMID: 37785456 DOI: 10.1016/j.ijrobp.2023.06.1640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Although clinical features of multi-parametric magnetic resonance imaging (mpMRI) have been associated with biochemical recurrence in localized prostate cancer, such features are subject to inter-observer variability. We evaluated whether the volume of the dominant intraprostatic lesion (DIL), as provided by a deep learning segmentation algorithm, could provide prognostic information for patients treated with definitive radiation therapy (RT). MATERIALS/METHODS We conducted a retrospective study of 438 patients with localized prostate cancer who underwent an endorectal coil, high B-value, 3-Tesla mpMRI and were treated with definitive RT at our institution between 2010 and 2017. We utilized the publicly available nnUNet to train a segmentation model which was used to identify the DIL. We examined the association between the artificial intelligence (AI)-generated DIL volume and oncologic outcomes, including biochemical recurrence and metastasis risk, using cause-specific Cox regression and time-dependent receiver operating characteristic analysis. RESULTS The AI model identified DILs with an area under the receiver operating characteristic (AUROC) of 0.827 at the patient level. For the 233 patients with available PI-RADS scores, with a median follow-up of 5.6 years, there were 28 biochemical failures. AI-defined DIL volume was significantly associated with biochemical failure (adjusted hazard ratio 1.60, 95% confidence interval 1.14-2.24, p = 0.007) after adjustment for PI-RADS score. Among all 438 patients with a median follow-up of 6.9 years, there were 49 biochemical failures and 22 metastases. The AUROC for predicting 7-year biochemical failure for AI volume (0.790) was similar to that for National Comprehensive Cancer Network (NCCN) category (p = 0.17). The AUROC for predicting 7-year metastasis for AI volume trended towards being higher compared to NCCN category (0.854 vs 0.769, p = 0.06). CONCLUSION An AI algorithm using deep learning could identify the DIL with good performance. AI-defined DIL volume may be able to provide prognostic information independent of the NCCN risk group or other radiologic factors for patients with localized prostate cancer treated with RT.
Collapse
Affiliation(s)
- D D Yang
- Harvard Radiation Oncology Program, Boston, MA
| | - L K Lee
- Department of Radiology, Brigham and Women's Hospital, Boston, MA
| | - J M G Tsui
- McGill University Health Center, Montreal, QC, Canada
| | - J E Leeman
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - K N Lee
- Harvard Radiation Oncology Program, Boston, MA
| | | | - A Sudhyadhom
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - C V Guthier
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - K W Mouw
- Broad Institute of MIT and Harvard, Cambridge, MA
| | - N E Martin
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - P F Orio
- Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - P L Nguyen
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
| | - A V DAmico
- Brigham and Women's Hospital, Boston, MA
| | - M T King
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA
| |
Collapse
|
2
|
Lee KN, Neibart SS, Droznin A, Guthier CV, Martin NE, Mancias JD, Lam M, Shiloh R, Peng LC, Ng K, Surana R, Enzinger P, Meyerhardt J, Mamon HJ. A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e312-e313. [PMID: 37785125 DOI: 10.1016/j.ijrobp.2023.06.2341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There has been increased interest in the use of short course hypofractionated radiotherapy as part of a total neoadjuvant treatment (TNT) approach in the management of rectal cancer since publication of the RAPIDO trial. However, the literature on short course radiation for rectal cancer has not reported significant acute toxicities in the weeks immediately following the completion of treatment. Anecdotally, a subset of patients has experienced acute neuropathic pain characterized in a lumbosacral distribution. This study investigates acute lumbosacral toxicity for patients receiving hypofractionated short course radiation as part of their definitive treatment for rectal cancer. MATERIALS/METHODS We retrospectively analyzed 75 patients with locally advanced rectal adenocarcinoma treated with hypofractionated short course radiation (25 Gy in 5 fractions) at our institution between 2016 and 2022. Acute toxicity caused by radiation was defined as that occurring from the start of radiation treatment to either 30 days post radiation completion, the start of chemotherapy, or date of surgery, whichever occurred first. RESULTS Among 75 patients treated with hypofractionated short course preoperative radiation with definitive intent, we identified 10 patients (13.3%) who experienced significant lumbosacral neuropathic pain and initiated a report to their medical providers during the acute toxicity time frame. Commonly, this was described as an achy pain in the bilateral buttocks radiating down to the knees or posterior claves. Patients rated this pain between moderate to extreme and management included steroids after failure of improvement with conservative measures, gabapentin, and conservative treatment with NSAIDs and Tylenol. Average time to onset of acute lumbosacral neuropathic pain was 3.7 days (SD 2.05) from start of RT. CONCLUSION We have identified a previously underappreciated acute toxicity of neuropathic lumbosacral pain in short course hypofractionated radiation therapy, which may be due to a lumbosacral plexus toxicity. Further analysis will seek to identify predictive factors such as comorbidities and dose to the lumbosacral plexus, and to determine whether there is a correlation between these observed acute toxicities and long-term outcomes.
Collapse
Affiliation(s)
- K N Lee
- Harvard Radiation Oncology Program, Boston, MA
| | - S S Neibart
- Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | - A Droznin
- Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston, MA
| | - C V Guthier
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - N E Martin
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - J D Mancias
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA
| | - M Lam
- Dana Farber Cancer Institute / Brigham & Women's Hospital, Boston, MA
| | - R Shiloh
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA
| | - L C Peng
- Department of Radiation Oncology, Dana-Farber Brigham Cancer Center, Boston, MA
| | - K Ng
- Dana Farber Cancer Institute, Boston, MA
| | - R Surana
- Dana Farber Cancer Institute, Boston, MA
| | - P Enzinger
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | | | - H J Mamon
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
3
|
Harris TC, Seco J, Ferguson D, Jacobson M, Myronakis M, Lozano IV, Lehmann M, Huber P, Fueglistaller R, Morf D, Mamon HJ, Mancias JD, Martin NE, Berbeco RI. Improvements in beam's eye view fiducial tracking using a novel multilayer imager. Phys Med Biol 2021; 66:10.1088/1361-6560/ac1246. [PMID: 34233309 PMCID: PMC11102774 DOI: 10.1088/1361-6560/ac1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 07/07/2021] [Indexed: 11/12/2022]
Abstract
Purpose.Electronic portal image devices (EPIDs) have been investigated previously for beams-eye view (BEV) applications such as tumor tracking but are limited by low contrast-to-noise ratio and detective quantum efficiency. A novel multilayer imager (MLI), consisting of four stacked flat-panels was used to measure improvements in fiducial tracking during liver stereotactic body radiation therapy (SBRT) procedures compared to a single layer EPID.Methods.The prototype MLI was installed on a clinical TrueBeam linac in place of the conventional DMI single-layer EPID. The panel was extended during volumetric modulated arc therapy SBRT treatments in order to passively acquire data during therapy. Images were acquired for six patients receiving SBRT to liver metastases over two fractions each, one with the MLI using all 4 layers and one with the MLI using the top layer only, representing a standard EPID. The acquired frames were processed by a previously published tracking algorithm modified to identify implanted radiopaque fiducials. Truth data was determined using respiratory traces combined with partial manual tracking. Results for 4- and 1-layer mode were compared against truth data for tracking accuracy and efficiency. Tracking and noise improvements as a function of gantry angle were determined.Results. Tracking efficiency with 4-layers improved to 82.8% versus 58.4% for the 1-layer mode, a relative improvement of 41.7%. Fiducial tracking with 1-layer returned a root mean square error (RMSE) of 2.1 mm compared to 4-layer RMSE of 1.5 mm, a statistically significant (p < 0.001) improvement of 0.6 mm. The reduction in noise correlated with an increase in successfully tracked frames (r = 0.913) and with increased tracking accuracy (0.927).Conclusion. Increases in MV photon detection efficiency by utilization of a MLI results in improved fiducial tracking for liver SBRT treatments. Future clinical applications utilizing BEV imaging may be enhanced by including similar noise reduction strategies.
Collapse
Affiliation(s)
- T C Harris
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
- BioMedical Physics in Radiation Oncology, DKFZ, Heidelberg, Germany
- Department of Physics, University of Heidelberg, Heidelberg, Germany
| | - J Seco
- BioMedical Physics in Radiation Oncology, DKFZ, Heidelberg, Germany
- Department of Physics, University of Heidelberg, Heidelberg, Germany
| | - D Ferguson
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States of America
| | - M Jacobson
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - M Myronakis
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - I Valencia Lozano
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - M Lehmann
- Varian Medical Systems, Baden-Dattwil, Switzerland
| | - P Huber
- Varian Medical Systems, Baden-Dattwil, Switzerland
| | | | - D Morf
- Varian Medical Systems, Baden-Dattwil, Switzerland
| | - H J Mamon
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - J D Mancias
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - N E Martin
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| | - R I Berbeco
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States of America
| |
Collapse
|
4
|
Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol 2018; 28:1098-1104. [PMID: 28453693 DOI: 10.1093/annonc/mdx041] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Background In 2012, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, despite evidence that Black men are at a higher risk of prostate cancer-specific mortality (PCSM). We evaluated whether Black men of potentially screening-eligible age (55-69 years) are at a disproportionally high risk of poor outcomes. Patients and methods The SEER database was used to study 390 259 men diagnosed with prostate cancer in the United States between 2004 and 2011. Multivariable logistic regression modeled the association between Black race and stage of presentation, while Fine-Gray competing risks regression modeled the association between Black race and PCSM, both as a function of screening eligibility (age 55-69 years versus not). Results Black men were more likely to present with metastatic disease (adjusted odds ratio [AOR] 1.65; 1.58-1.72; P < 0.001) and were at a higher risk of PCSM (adjusted hazard ratio [AHR] 1.36; 1.27-1.46; P < 0.001) compared to non-Black men. There were significant interactions between race and PSA-screening eligibility such that Black patients experienced more disproportionate rates of metastatic disease (AOR 1.76; 1.65-1.87 versus 1.55; 1.47-1.65; Pinteraction < 0.001) and PCSM (AHR 1.53; 1.37-1.70 versus 1.25; 1.14-1.37; Pinteraction = 0.01) in the potentially PSA-screening eligible group than in the group not eligible for screening. Conclusions Racial disparities in prostate cancer outcome among Black men are significantly worse in PSA-screening eligible populations. These results raise the possibility that Black men could be disproportionately impacted by recommendations to end PSA screening in the United States and suggest that Black race should be included in the updated USPSTF PSA screening guidelines.
Collapse
Affiliation(s)
- B A Mahal
- Harvard Radiation Oncology Program, Boston, USA.,Harvard Medical School, Boston, USA
| | - Y-W Chen
- Harvard Medical School, Boston, USA.,Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| | - V Muralidhar
- Harvard Medical School, Boston, USA.,Deparment of Internal Medicine, Brigham and Women's Hospital, Boston, USA
| | - A R Mahal
- Department of Therapeutic Radiology/Radiation Oncology, Yale, New Haven, USA
| | - T K Choueiri
- Harvard Medical School, Boston, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| | - K E Hoffman
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J C Hu
- Department of Urology, Cornell (New York-Presbyterian Hospital), New York, USA
| | - C J Sweeney
- Harvard Medical School, Boston, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| | - J B Yu
- Department of Therapeutic Radiology/Radiation Oncology, Yale, New Haven, USA
| | - F Y Feng
- Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA
| | - S P Kim
- Department of Urology, Case Western Reserve University School of Medicine (University Hospitals), Cleveland, USA
| | - C J Beard
- Harvard Medical School, Boston, USA.,Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| | - N E Martin
- Harvard Medical School, Boston, USA.,Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| | - Q-D Trinh
- Harvard Medical School, Boston, USA.,Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | - P L Nguyen
- Harvard Medical School, Boston, USA.,Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA
| |
Collapse
|
5
|
Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Dis Esophagus 2017; 30:1-8. [PMID: 28475728 DOI: 10.1093/dote/dox025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Accepted: 03/06/2017] [Indexed: 12/11/2022]
Abstract
Preoperative chemoradiotherapy (CRT) with carboplatin/paclitaxel has been shown to increase survival in patients with esophageal cancer, including gastroesophageal junction (GE) junction cancer, over surgery alone; however, there have been no studies comparing the different neoadjuvant CRT regimens. We retrospectively evaluated the long-term results of trimodality therapy for patients with locally advanced esophageal cancer treated on several chemotherapy regimens. Between 1999 and 2014, 215 patients with locally advanced esophageal cancer underwent neoadjuvant CRT followed by surgical resection. The median age was 62 years (range 21-84), 80.5% were men and 86% had adenocarcinoma. The following chemotherapy regimens were administered: cisplatin/5FU (14.9%), cisplatin/irinotecan (35.8%), carboplatin/paclitaxel (35.8%), and other (9.7%). The majority of patients (92.1%) received a radiation dose of 50.4 Gy. Predictors of toxicities and surgical complications were assessed using logistic regression. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method and proportional hazards regression was used to model time-to-event outcomes. The median follow-up among surviving patients was 4.1 years (range 0.4,13). The median OS was 3.0 years from time of diagnosis and OS was 36.8% at 5 years. RFS was 34.9% at 5 years. After neoadjuvant CRT, 34.7% of patients achieved a pathologic complete response including 60.7% of squamous cell carcinoma patients and 18.4% of adenocarcinoma patients (P < 0.001) and 66% were downstaged. Of the variables examined, pathologic stage, preoperative baseline cardiac comorbidity, postoperative cardiac or pulmonary complications, and chemotherapy regimen were associated with OS. Using cisplatin and 5FU as the reference regimen, patients treated with carboplatin/paclitaxel had significantly improved OS (HR = 0.47, P = 0.017 after adjusting for surgery type, radiation modality, baseline cardiac comorbidity, and preoperative stage) with 5-year OS rate of 66%. The most common surgical complications were cardiac in 61 patients (28.5%) and pulmonary in 52 patients (24.3%). Cardiac complications were associated with age (OR 1.05, P = 0.007) and cardiac comorbidity (OR 2.6, P = 0.02) and pulmonary complications with female gender (OR 3.98, P < 0.001). Forty-four patients (20.5%) required readmission within 30 days of discharge, and readmission was associated with cardiac comorbidity (OR 2.7, P = 0.017). Three patients died within 30 days of surgery. We observed an association between neoadjuvant carboplatin/paclitaxel and improved overall survival that requires confirmation in a prospective randomized trial.
Collapse
Affiliation(s)
| | - P J Catalano
- Departments of Biostatistics and Computational Biology
| | | | - B L King
- Departments of Radiation Oncology
| | - R Bueno
- Thoracic Surgery, Brigham and Women's Hospital
| | | | - T S Hong
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States
| | - J Y Wo
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States
| | | |
Collapse
|
6
|
Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis 2017; 20:186-192. [PMID: 28117383 PMCID: PMC5435968 DOI: 10.1038/pcan.2016.58] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 09/14/2016] [Accepted: 10/12/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction. GC scores (range, 0.04-0.92) were determined. The primary end point of the study was time to distant metastasis. Median follow-up was 5.1 years. There were 18 metastases during the study period. RESULTS On univariable analysis (UVA), each 0.1 unit increase in GC score was significantly associated with time to distant metastasis (hazard ratio: 1.40 (1.10-1.84), P=0.006) and remained significant after adjusting for clinical variables on multivariable analysis (MVA) (adjusted hazard ratio: 1.36 (1.04-1.83), P=0.024). The c-index for 5-year distant metastasis was 0.45 (95% confidence interval: 0.27-0.64) for Cancer of the Prostate Risk Assessment score, 0.63 (0.40-0.78) for National Comprehensive Cancer Network (NCCN) risk groups, and 0.76 (0.57-0.89) for the GC score. Using pre-specified GC risk categories, the cumulative incidence of metastasis for GC>0.6 reached 20% at 5 years after radiation (P=0.02). CONCLUSIONS We believe this is the first demonstration of the ability of the biopsy-based GC score to predict for distant metastases after definitive radiation and ADT for intermediate- and high-risk prostate cancer. Patients with the highest GC risk (GC>0.6) had high rates of metastasis despite multi-modal therapy suggesting that they could potentially be candidates for treatment intensification and/or enrollment in clinical trials of novel therapy.
Collapse
Affiliation(s)
- P L Nguyen
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - N E Martin
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - V Choeurng
- GenomeDx Biosciences, Vancouver, BC, Canada
| | | | - T Kolisnik
- GenomeDx Biosciences, Vancouver, BC, Canada
| | - C J Beard
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - P F Orio
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - M D Nezolosky
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - Y-W Chen
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA
| | - H Shin
- GenomeDx Biosciences, Vancouver, BC, Canada
| | | | - F Y Feng
- Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA
| |
Collapse
|
7
|
Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol 2014; 26:399-406. [PMID: 25430935 DOI: 10.1093/annonc/mdu534] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Death within 1 month of surgery is considered treatment related and serves as an important health care quality metric. We sought to identify the incidence of and factors associated with 1-month mortality after cancer-directed surgery. PATIENTS AND METHODS We used the Surveillance, Epidemiology and End Results Program to study a cohort of 1 110 236 patients diagnosed from 2004 to 2011 with cancers that are among the 10 most common or most fatal who received cancer-directed surgery. Multivariable logistic regression analyses were used to identify factors associated with 1-month mortality after cancer-directed surgery. RESULTS A total of 53 498 patients (4.8%) died within 1 month of cancer-directed surgery. Patients who were married, insured, or who had a top 50th percentile income or educational status had lower odds of 1-month mortality from cancer-directed surgery {[adjusted odds ratio (AOR) 0.80; 95% confidence interval (CI) 0.79-0.82; P < 0.001], (AOR 0.88; 95% CI 0.82-0.94; P < 0.001), (AOR 0.95; 95% CI 0.93-0.97; P < 0.001), and (AOR 0.98; 95% CI 0.96-0.99; P = 0.043), respectively}. Patients who were non-white minority, male, or older (per year increase), or who had advanced tumor stage 4 disease all had a higher risk of 1-month mortality after cancer-directed surgery, with AORs of 1.13 (95% CI 1.11-1.15), P < 0.001; 1.11 (95% CI 1.08-1.13), P < 0.001; 1.02 (95% 1.02-1.03), P < 0.001; and 1.89 (95% CI 1.82-1.95), P < 0.001 respectively. CONCLUSIONS Unmarried, uninsured, non-white, male, older, less educated, and poorer patients were all at a significantly higher risk for death within 1 month of cancer-directed surgery. Efforts to reduce 1-month surgical mortality and eliminate sociodemographic disparities in this adverse outcome could significantly improve survival among patients with cancer.
Collapse
Affiliation(s)
- B A Mahal
- Department of Medical Oncology, Harvard Medical School
| | | | | | - D R Ziehr
- Department of Medical Oncology, Harvard Medical School
| | | | - T K Choueiri
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston
| | - K E Hoffman
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - J C Hu
- Department of Urology, UCLA Medical Center, Los Angeles
| | | | | | | | - P F Orio
- Department of Radiation Oncology
| | - Q-D Trinh
- Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | | |
Collapse
|
8
|
Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67:619-32. [PMID: 23692526 PMCID: PMC3752932 DOI: 10.1111/ijcp.12194] [Citation(s) in RCA: 158] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Accepted: 04/20/2013] [Indexed: 02/04/2023] Open
Abstract
INTRODUCTION To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. METHODS This prespecified pooled analysis of three randomised, double-blind, placebo-controlled, 12-week studies, evaluated efficacy and safety of once-daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and tolterodine ER 4 mg (safety analysis) for the treatment of symptoms of overactive bladder (OAB). Co-primary efficacy measures were change from baseline to Final Visit in the mean number of incontinence episodes/24 h and mean number of micturitions/24 h. Key secondary efficacy end-points included mean number of urgency episodes/24 h and mean volume voided/micturitions, while other end-points included patient-reported outcomes according to the Treatment Satisfaction-Visual Analogue Scale (TS-VAS) and responder analyses [dry rate (posttreatment), ≥ 50% reduction in incontinence episodes/24 h, ≤ 8 micturitions/24 h (post hoc analysis)]. The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate). RESULTS Mirabegron (50 and 100 mg once daily) demonstrated statistically significant improvements compared with placebo for the co-primary end-points, key secondary efficacy variables, TS-VAS and responder analyses (all comparisons p < 0.05). Mirabegron is well tolerated and demonstrates a good safety profile. The most common AEs (≥ 3%) included hypertension, nasopharyngitis and urinary tract infection (UTI); the incidence of hypertensive events and UTIs decreased with increasing dose. For mirabegron, the incidence of the bothersome antimuscarinic AE, dry mouth, was at placebo level and of a lesser magnitude than tolterodine. CONCLUSION The efficacy and safety of mirabegron are demonstrated in this large pooled clinical trial dataset in patients with OAB.
Collapse
Affiliation(s)
- V W Nitti
- Department of Urology, NYU Langone Medical Center, New York, NY, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Martin NE, Chen M, Nguyen PL, Beard C, Kantoff PW, D'Amico AV. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and six months of combined androgen blockade. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
191 Background: An increased duration of testosterone (T) suppression (TS) after 6 months (mo) of combined hormonal blockade (CHB) with an LHRH agonist and an anti-androgen plus external beam radiation therapy (RT) is associated with decreased mortality. We investigated whether the biopsy Gleason score (BGS) was associated with duration of TS. Methods: The study cohort consisted of 120 men with node negative prostate cancer (PCa) treated with RT and 6 mo of CHB between 1996 and 2005 at a single academic and associated suburban center. We defined the duration of TS as the time between the last day of CHB and the date the T returned to ≥252 ng/dL (10% below the lower limit of normal on the assay used). We used Cox regression multivariable analysis to determine whether BGS was significantly associated with the duration of TS following cessation of CHB adjusting for age, PSA, baseline T, clinical tumor category, body mass index and a history of diabetes mellitus. Results: The median age of the cohort was 70.1 years (IQR: 64.7, 73.9). The median time to T rebound (MTR) was 19.5 mo for all men (table). BGS 8-10 had an adjusted hazard ratio (AHR) of 1.85 (95% confidence interval [CI] 1.06-3.22; p=0.03) indicating a faster time to T rebound. Specifically men with BGS 8-10 had a MTR of 14.0 mo compared to 19.5 and 22.4 mo for the Gleason ≤6 and 7 respectively. Increasing age was significantly associated with a longer duration of TS [AHR of 0.95 (95% CI 0.92-0.98; p<0.001)]. Conclusions: A BGS of 8-10 is associated with a shorter period of TS following 6 mo of CHB + RT. These data are consistent with the hypothesis that a factor released from high grade PCa cells may impact T production. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. E. Martin
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| | - M. Chen
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| | - P. L. Nguyen
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| | - C. Beard
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| | - P. W. Kantoff
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| | - A. V. D'Amico
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; University of Connecticut, Storrs, CT; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
10
|
Martin NE, Brunner TB, Bernhard EJ, Kiel KD, Delaney TF, Regine WF, Morrison BW, Tanaka WK, McKenna WG, Hahn SM. A phase I trial of the farnesyltransferase and geranylgeranyltransferase-I inhibitor L-778,123 (L-778) and radiotherapy for locally advanced pancreatic cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. E. Martin
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - T. B. Brunner
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - E. J. Bernhard
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - K. D. Kiel
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - T. F. Delaney
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - W. F. Regine
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - B. W. Morrison
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - W. K. Tanaka
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - W. G. McKenna
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| | - S. M. Hahn
- University of Pennsylvania School of Medicine, Philadelphia, PA; Northwestern Memorial Hospital, Chicago, IL; Boston University Medical Center, Boston, MA; University of Kentucky, Lexington, KY; Merck Research Laboratory, Rahway, NJ
| |
Collapse
|
11
|
Abstract
The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e. phospholipid bilayer vehicles) have been effective in decreasing the clearance of encapsulated agents and in passively targeting specific tissues, they are associated with considerable limitations. Pegylation may be an effective method of delivering therapeutic proteins and modifying their pharmacokinetic properties, in turn modifying pharmacodynamics, via a mechanism dependent on altered binding properties of the native protein. Pegylation reduces renal clearance and, for some products, results in a more sustained absorption after subcutaneous administration as well as restricted distribution. These pharmacokinetic changes may result in more constant and sustained plasma concentrations, which can lead to increases in clinical effectiveness when the desired effects are concentration-dependent. Maintaining drug concentrations at or near a target concentration for an extended period of time is often clinically advantageous, and is particularly useful in antiviral therapy, since constant antiviral pressure should prevent replication and may thereby suppress the emergence of resistant variants. Additionally, PEG modification may decrease adverse effects caused by the large variations in peak-to-trough plasma drug concentrations associated with frequent administration and by the immunogenicity of unmodified proteins. Pegylated proteins may have reduced immunogenicity because PEG-induced steric hindrance can prevent immune recognition. Two PEG-modified proteins are currently approved by the US Food and Drug Administration; several others, including cytokines such as interferon-alpha (IFNalpha), growth factors and free radical scavengers, are under development. Careful assessment of various pegylated IFNalpha products suggests that pegylated molecules can be differentiated on the basis of their pharmacokinetic properties and related changes in pharmacodynamics. Because the size, geometry and attachment site of the PEG moiety play a crucial role in determining these properties, therapeutically optimised agents must be designed on a protein-by-protein basis.
Collapse
Affiliation(s)
- J M Harris
- Shearwater Corporation, Huntsville, Alabama 35801, USA.
| | | | | |
Collapse
|
12
|
Abstract
To assess oxidant stress responses in newborn infants treated with elevated concentrations of oxygen, we measured plasma concentrations of glutathione (GSH) and glutathione disulfide (GSSG) in newborn infants ranging from 23 to 42 wk gestational age. All infants recruited into the study were mechanically ventilated and had catheters placed in their umbilical arteries as part of their normal clinical management. Blood samples were obtained on d 1, 3, and 5 and weekly thereafter or until the catheters were removed. We observed plasma concentrations of GSSG in these infants that were frequently an order of magnitude higher than the 0.1 to 0.3 microM we find in adults. Interestingly, plasma GSSG concentrations were inversely correlated to the inspired oxygen tensions. This effect appeared to arise from the patient selection criteria whereby, of the infants studied, those breathing the lowest partial pressures of oxygen were the smallest and gestationally youngest. A second observation was that plasma concentrations of GSH in the premature infants were substantially, indeed often dramatically, lower than we have observed in adult humans (6 to 10 microM). Finally, we found that in patients with both umbilical arterial and umbilical venous catheters arterial GSSG concentrations were consistently higher than venous concentrations; conversely, arterial GSH concentrations were lower than venous concentrations. The elevated GSSG concentrations we observed in these infants indicate marked oxidant stress responses in prematurely born infants, even in those infants exposed only to room air. The positive arteriovenous gradients of GSSG concentrations across the lungs of these infants suggest that at least some of the increased plasma GSSG originates in the lung.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- C V Smith
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030
| | | | | | | | | |
Collapse
|